Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hyperalgesia is an increase in pain response. Predisposing factors include long-term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves, and psychological disorders. Treatment includes antidepressants and non-steroidal anti-inflammatory drugs.
The hyperalgesia drugs in development report provides an overview of the hyperalgesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects.
What are the targets of the hyperalgesia pipeline drugs market?
The targets of the Hyperalgesia pipeline drugs market are Delta Type Opioid Receptor, Kappa Type Opioid Receptor, Mu Type Opioid Receptor, Phospholipase A2, Probable G Protein Coupled Receptor 19, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Transforming Growth Factor Beta 1, and Tryptophan 5 Hydroxylase 1.
Hyperalgesia pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the hyperalgesia pipeline drugs market?
The mechanisms of action of the hyperalgesia pipeline drugs market are Delta Type Opioid Receptor Agonist, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Phospholipase A2 Inhibitor, Probable G Protein Coupled Receptor 19 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, and Tryptophan 5 Hydroxylase 1 Inhibitor.
Hyperalgesia pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the hyperalgesia pipeline drugs market?
The routes of administration in the hyperalgesia pipeline drugs market are oral and topical.
Hyperalgesia pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the hyperalgesia pipeline drugs market?
The molecule types in the hyperalgesia pipeline drugs market are small molecule, monoclonal antibody, peptide, and synthetic peptide.
Hyperalgesia pipeline drugs market, by molecule types
For more molecule types insights, download a free report sample
Which are the key companies in the hyperalgesia pipeline drugs market?
Some of the key companies in the hyperalgesia pipeline drugs market are Caventure Drug Discovery Inc, Charleston Laboratories Inc, Exodos Life Sciences Limited Partnership, and Novartis AG.
Hyperalgesia pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
Targets | Delta Type Opioid Receptor, Kappa Type Opioid Receptor, Mu Type Opioid Receptor, Phospholipase A2, Probable G Protein Coupled Receptor 19, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Transforming Growth Factor Beta 1, and Tryptophan 5 Hydroxylase 1 |
Mechanisms of Action | Delta Type Opioid Receptor Agonist, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Phospholipase A2 Inhibitor, Probable G Protein Coupled Receptor 19 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, and Tryptophan 5 Hydroxylase 1 Inhibitor |
Routes of Administration | Oral and Topical |
Molecule Types | Small Molecule, Monoclonal Antibody, Peptide, and Synthetic Peptide |
Key Companies | Caventure Drug Discovery Inc, Charleston Laboratories Inc, Exodos Life Sciences Limited Partnership, and Novartis AG |
This report provides:
- A snapshot of the global therapeutic landscape of Hyperalgesia (Central Nervous System).
- Reviews of pipeline therapeutics for Hyperalgesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Hyperalgesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Hyperalgesia (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperalgesia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperalgesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Charleston Laboratories Inc
Exodos Life Sciences Limited Partnership
Novartis AG
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the hyperalgesia pipeline drugs market?
The targets of the hyperalgesia pipeline drugs market are Delta Type Opioid Receptor, Kappa Type Opioid Receptor, Mu Type Opioid Receptor, Phospholipase A2, Probable G Protein Coupled Receptor 19, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Transforming Growth Factor Beta 1, and Tryptophan 5 Hydroxylase 1.
-
What are the mechanisms of action of the hyperalgesia pipeline drugs market?
The mechanisms of action of the hyperalgesia pipeline drugs market are Delta Type Opioid Receptor Agonist, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Phospholipase A2 Inhibitor, Probable G Protein Coupled Receptor 19 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, and Tryptophan 5 Hydroxylase 1 Inhibitor.
-
What are the routes of administration in the hyperalgesia pipeline drugs market?
The routes of administration in the hyperalgesia pipeline drugs market are oral and topical.
-
What are the molecule types in the hyperalgesia pipeline drugs market?
The molecule types in the Hyperalgesia pipeline drugs market are small molecule, monoclonal antibody, peptide, and synthetic peptide.
-
Which are the key companies in the hyperalgesia pipeline drugs market?
Some of the key companies in the Hyperalgesia pipeline drugs market are Caventure Drug Discovery Inc, Charleston Laboratories Inc, Exodos Life Sciences Limited Partnership, and Novartis AG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.